Jing S Ma

US Patent:

7228521, Jun 5, 2007

Filed:

Feb 1, 2005

Appl. No.:

11/048333

Inventors:

Jing Hua Ma - San Jose CA, US
Benhai Zhang - San Jose CA, US

Assignee:

XILINX Inc. - San Jose CA

International Classification:

G06F 17/50
H03K 19/00

US Classification:

716 17, 716 12, 716 14

Abstract:

A code is generated for a programmable logic device (“PLD”) having a plurality of regions including at least one defective region. The code indicates a defective region or regions of the PLD. A user enters the code before running placement and routing. A guide file associated with the code blocks out the defective region(s) of the PLD during placement and routing.

US Patent:

20040146509, Jul 29, 2004

Filed:

Jul 23, 2003

Appl. No.:

10/626004

Inventors:

Zhihe Li - Foster City CA, US
David Liu - Palo Alto CA, US
Jing Ma - Cupertino CA, US
Andrew Protter - Palo Alto CA, US
George Schreiner - Los Altos CA, US

International Classification:

A61K039/395

US Classification:

424/144100

Abstract:

The invention concerns methods for improvement of lung function by administering non-peptide small molecule inhibitors of TGF- specifically binding to the type I TGF- receptor (TGF-R1). Preferably, the inhibitors are quinazoline derivatives.

US Patent:

20050232926, Oct 20, 2005

Filed:

Dec 2, 2004

Appl. No.:

11/004659

Inventors:

Jing Ma - Laguna Niguel CA, US
Yanjun Guo - Shanghai, CN

International Classification:

A61K039/395
C07H021/04
C12N015/09
C12N005/06
C07K016/30

US Classification:

424155100, 435069100, 435320100, 530388800, 536023530, 435344000

Abstract:

The invention concerns antibodies which is specific for SM5-1 antigen expressed in melanoma, breast cancer and hepatocellular carcinoma, and polynucleotides encoding the antibodies. The invention further concerns use of such antibodies and/or polynucleotides in diagnosing and treating malignancies.

US Patent:

20050232931, Oct 20, 2005

Filed:

Dec 2, 2004

Appl. No.:

11/004639

Inventors:

Jing Ma - Laguna Niguel CA, US
Yanjun Guo - Shanghai, CN

International Classification:

A61K039/00
C07K014/82

US Classification:

424185100, 530350000

Abstract:

Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinaceous or peptidyl tumoricidal agent, or a targeting agent which binds to a receptor expressed on a tumor, and uses thereof, particularly in the treatment of malignancy. Other embodiments and uses are disclosed.

US Patent:

20210017120, Jan 21, 2021

Filed:

Sep 29, 2020

Appl. No.:

17/036588

Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US

Assignee:

OBI PHARMA, INC. - Taipei City

International Classification:

C07C 217/58
C07D 405/12
C07F 9/6558
A61K 47/64
C07D 403/06
A61K 47/55
A61P 35/00
C07D 239/94
C07D 487/04
C07D 471/04
C07C 213/02
C07D 491/22
C07H 19/06

Abstract:

Provided herein are compounds of formula I:wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

US Patent:

20190225633, Jul 25, 2019

Filed:

Mar 28, 2019

Appl. No.:

16/368753

Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US

Assignee:

OBI PHARMA, INC. - Taipei City

International Classification:

C07F 9/24
G01N 33/574
A61K 31/396

Abstract:

Provided herein are compounds of formula I:wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

US Patent:

20180258116, Sep 13, 2018

Filed:

Nov 15, 2016

Appl. No.:

15/752854

Inventors:

- Taipei City, TW
Yeyu Cao - South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Mark Matteucci - South San Francisco CA, US

Assignee:

OBI Pharma, Inc. - Taipei City

International Classification:

C07F 9/564
A61P 35/00

Abstract:

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.

US Patent:

20180169064, Jun 21, 2018

Filed:

Jun 23, 2016

Appl. No.:

15/736285

Inventors:

- South San Francisco CA, US
Xiaohong Cai - South San Francisco CA, US
Yeyu Cao - South San Francisco CA, US
Hailong Jiao - South San Francisco CA, US
Jing Yuan Ma - South San Francisco CA, US
Jian-Xin Duan - South San Francisco CA, US

International Classification:

A61K 31/396
A61K 31/4168
A61K 31/4178
A61K 31/665
A61K 31/675
A61P 35/00

Abstract:

Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.